Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update

References

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41. doi:10.1016/j.jacc.2013.10.02924355639
   PubMed Web of Science ®Google Scholar
• McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D51–D59. doi:10.1016/j.jacc.2013.10.02324355642
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery, JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.26320113
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Wedzicha JA, Iversen M, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50:1700740. doi:10.1183/13993003.00711-201728775047
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818. doi:10.1056/NEJMoa121391723984728
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012;91:517–521. doi:10.1016/j.lfs.2012.07.03322884806
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Inoue A, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. J Cardiovasc Pharmacol. 1989;13:S13–S17.
   Web of Science ®Google Scholar
• Clarke J, Benjamin NI, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989;257:H2033–H2035. doi:10.1152/ajpheart.1989.257.6.H20332690644
   PubMed Web of Science ®Google Scholar
• Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:S62–S67. doi:10.1016/j.jacc.2004.02.042
   PubMed Web of Science ®Google Scholar
• Stewart D, Levy R, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertesnion: marker or mediator of disease. Ann Intern Med. 1991;114:464–469. doi:10.7326/0003-4819-114-6-4641994793
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–1739. doi:10.1056/NEJM1993061732824028497283
   PubMed Web of Science ®Google Scholar
• Davie N, Haleen SJ, Upton PD. et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398–405. doi:10.1164/ajrccm.165.8.210610411818328
   PubMed Web of Science ®Google Scholar
• Wilson DW, Segall HJ, Pan LC, Lamé MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22:307–325. doi:10.3109/104084492091463111489509
   PubMed Web of Science ®Google Scholar
• Jasmin J-F, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET A/B and a selective ET A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001;103:314–318. doi:10.1161/01.CIR.103.2.31411208695
   PubMed Web of Science ®Google Scholar
• Lai Y-C, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115:115–130. doi:10.1161/CIRCRESAHA.115.30114624951762
   PubMed Web of Science ®Google Scholar
• Selej M, Romero AJ, Channick RN, Clozel M. Development of macitentan for the treatment of pulmonary arterial hypertension: macitentan for the treatment of pulmonary arterial hypertension. Ann N Y Acad Sci. 2015;1358:68–81. doi:10.1111/nyas.1285626291180
   PubMed Web of Science ®Google Scholar
• Hong IS. Macitentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2014;48:538–547. doi:10.1177/1060028013518900
   Web of Science ®Google Scholar
• Iglarz M, Bossu A, Wanner D, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014;118:333–339. doi:10.1016/j.lfs.2014.02.01824582812
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PLM, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67:977–984. doi:10.1007/s00228-011-1043-221541781
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PLM, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects: the journal of clinical pharmacology. J Clin Pharmacol. 2013; n/a-n/a. doi:10.1002/jcph.152
   Web of Science ®Google Scholar
• Paul GA, Gibbs JSR, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60:107–112. doi:10.1111/j.1365-2125.2005.02383.x15963102
   PubMed Web of Science ®Google Scholar
• Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64:43–50. doi:10.1007/s00228-007-0408-z18040672
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PLM, Wolzt M, Dingemanse J. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects: pharmacokinetic interactions between macitentan and sildenafil. Br J Clin Pharmacol. 2014;78:1035–1042. doi:10.1111/bcp.1244724962473
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42:1622–1632. doi:10.1183/09031936.0010461223682110
   PubMed Web of Science ®Google Scholar
• Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations. JACC Heart Fail. 2015;3:1–8. doi:10.1016/j.jchf.2014.07.01325457902
   PubMed Web of Science ®Google Scholar
• Galiè N, Jansa P, Pulido T, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38:1147–1155. doi:10.1093/eurheartj/ehx02528329315
   PubMed Web of Science ®Google Scholar
• Mehta S, Sastry BKS, Souza R, et al. Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension. Chest. 2017;151:106–118. doi:10.1016/j.chest.2016.08.147327671974
   PubMed Web of Science ®Google Scholar
• Vanhoof JMM, Page RLEA, Ambardekar AV, Brieke A, Lindenfeld J. Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014;33:800–808. doi:10.1016/j.healun.2014.08.02224854567
   PubMed Web of Science ®Google Scholar
• Vachiéry J-L, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51:1701886. doi:10.1183/13993003.01886-201729437943
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, Casarin A, Ely EW, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785–794. doi:10.1016/S2213-2600(17)30234-528919201
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319–329. doi:10.1056/NEJMoa120965723883377
   PubMed Web of Science ®Google Scholar
• Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54. doi:10.1161/CIRCULATIONAHA.106.63071516801459
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of macitentan in patients with Eisenmenger syndrome. Circulation. 2019;139:51–63. doi:10.1161/CIRCULATIONAHA.118.03357530586694
   PubMed Web of Science ®Google Scholar
• Duo-Ji -M-M, Long Z-W. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: a network meta-analysis. Int J Cardiol. 2017;234:90–98. doi:10.1016/j.ijcard.2016.12.09228233631
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014;13:391–405. doi:10.1517/14740338.2014.85967424261583
   PubMed Web of Science ®Google Scholar
• Davila C, Monaco T. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2016;1675. doi:10.2147/DDDT.S88612
   Web of Science ®Google Scholar
• Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta‐analysis of 4894 patients from 24 randomized double‐blind placebo‐controlled clinical trials. J Am Heart Assoc. 2016;5. doi:10.1161/JAHA.116.003896
   Web of Science ®Google Scholar
• Trow T, Fares W, Kholdani C. Macitentan for the treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2014;665. doi:10.2147/VHRM.S3390425473292
   PubMedGoogle Scholar
• Vercauteren M, Strasser D, Vezzali E. et al. Vasopressin in involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists. Eur Respir J. 2012;40:716s. doi:10.1183/09031936.00213711
   Web of Science ®Google Scholar
• Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE. Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol- Ren Physiol. 2008;295:F1635–F1640. doi:10.1152/ajprenal.90279.2008
   Web of Science ®Google Scholar
• Shapiro S, Chun L, Patton KK, Matsushita MM, Page RL, Raskind WH. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110:1373–1377. doi:10.1016/j.amjcard.2012.07.03322858181
   PubMed Web of Science ®Google Scholar
• Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag. 2007;3:887–900.18200808
   PubMedGoogle Scholar
• Center for Drug Evaluation And Research; Approval Package for Macitentan. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000Approv.pdf. Accessed December 2, 2018.
   Google Scholar
• OPsumit users registry - full text view - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02126943. Accessed 122, 2018.
   Google Scholar
• Kim NH, Bergmark BA, Zelniker TA, et al. OPUS registry: safety and tolerability of macitentan in a real-world setting. J Heart Lung Transplant. 2017;36:S20–S21. doi:10.1016/j.healun.2017.06.015
   Web of Science ®Google Scholar
• Kim NH, Chin KM, Muros-Le Rouzic E. et al. OPsumit® USers Registry (OPUS): insights into the safety and tolerability of Opsumit® | D54. CLINICAL PULMONARY HYPERTENSION. Am J Respir Crit Care Med. 2016;A7396.
   Google Scholar
• Chin KM, Channick RN, Kim NH, et al. OPUS registry: treatment patterns with macitentan in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;195:A2299.
   Google Scholar
• Chin KM, Kim N, Channick R, Muros-Le Rouzic E, Selej M, McLaughlin V. OPUS registry: treatment patterns and safety of macitentan in patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (PAH-SSc). Chest. 2017;152:A999–A1000. doi:10.1016/j.chest.2017.08.1036
   Web of Science ®Google Scholar
• McLaughlin VV, Channick R, Chin KM, et al. The OPSUMIT Users Registry: a Gender Subgroup Analysis of Patient Characetistics, Treatment Patterns and Survival in Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2018;71(Supplement). doi:10.1016/S0735-1097(18)32493-8
   Web of Science ®Google Scholar
• FDA Opsumit Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf. Accessed 124, 2018.
   Google Scholar
• Monograph AO. Available from: https://www1.actelion.com/documents/ca/ca-opsumit-procuct-monograph-en.pdf. Accessed 124, 2018.
   Google Scholar
• Safdar Z, Thakur A, Frost A. Tolerability of switch to macitentan from bosentan in pulmonary arterial hypertension. South Med J. 2017;110:223–228. doi:10.14423/SMJ.000000000000073828257550
   PubMed Web of Science ®Google Scholar
• Blok I, van Riel AC, van Dijk AP, Mulder BJ, Bouma BJ. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: further improvement? Int J Cardiol. 2017;227:51–52. doi:10.1016/j.ijcard.2016.11.21127846462
   PubMed Web of Science ®Google Scholar
• Herbert S, Gin-Sing W, Howard L, Tulloh RMR. Early experience of macitentan for pulmonary arterial hypertension in adult congenital heart disease. Heart Lung Circ. 2017;26:1113–1116. doi:10.1016/j.hlc.2016.12.01128237536
   PubMed Web of Science ®Google Scholar
• Jansa P, Pulido T. Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the SERAPHIN trial. Am J Cardiovasc Drugs. 2018;18:1–11. doi:10.1007/s40256-017-0255-y29280064
   PubMed Web of Science ®Google Scholar
• The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension - full text view - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02558231. Accessed 1127, 2018.
   Google Scholar